Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial

被引：0
|
作者：
Motzer, Robert J.
Penkov, Konstantin
Uemura, Hirotsugu
Campbell, Matthew T.
Kollmannsberger, Christian K.
Lee, Jae-Lyun
Venugopal, Balaji
Van Den Eertwegh, Alfonsus
Negrier, Sylvie
Gurney, Howard
Albiges, Laurence
Berger, Raanan
Haanen, John
Rini, Brian I.
Larkin, James
Schmidinger, Manuela
Sandner, Robin
Wang, Jing
Di Pietro, Alessandra
Choueiri, Toni K.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Private Med Inst, Euromed Serv, St Petersburg, Russia
[3] Kindai Univ, Dept Urol, Fac Med, Osaka, Japan
[4] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Genitourinary Med Oncol, Houston, TX USA
[5] British Columbia Canc Agcy, Vancouver Ctr, Vancouver, BC, Canada
[6] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[7] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[8] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands
[9] Univ Lyon, Lyon, France
[10] Macquarie Univ, Dept Clin Med, Sydney, NSW, Australia
[11] Inst Gustave Roussy, Villejuif, France
[12] Chaim Sheba Med Ctr, Ramat Gan, Israel
[13] Netherlands Canc Inst, Amsterdam, Netherlands
[14] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[15] Royal Marsden Hosp NHS Fdn Trust, London, England
[16] Med Univ Vienna, Vienna, Austria
[17] Pfizer Inc, Collegeville, PA USA
[18] Pfizer Inc, Cambridge, MA USA
[19] Pfizer SRL, Milan, Italy
[20] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4508
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial
    Grimm, Marc-Oliver
    Oya, Mototsugu
    Choueiri, Toni K.
    Motzer, Robert J.
    Schmidinger, Manuela
    Quinn, David I.
    Gravis-Mescam, Gwenaelle
    Verzoni, Elena
    Van den Eertwegh, Alfonsus J. M.
    di Pietro, Alessandra
    Mariani, Mariangela
    Wang, Jing
    Thomaidou, Despina
    Albiges, Laurence
    EUROPEAN UROLOGY, 2024, 85 (01) : 8 - 12
  • [22] First-line avelumab plus axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
    Choueiri, Toni K.
    Larkin, James M. G.
    Oya, Mototsugu
    Thistlethwaite, Fiona C.
    Martignoni, Marcella
    Nathan, Paul D.
    Powles, Thomas
    McDermott, David F.
    Robbins, Paul B.
    Chism, David D.
    Cho, Daniel C.
    Atkins, Michael B.
    Gordon, Michael S.
    Gupta, Sumati
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Compagnoni, Anna
    Di Pietro, Alessandra
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow- up results from JAVELIN Renal 101.
    Haanen, John B. A. G.
    Larkin, James
    Choueiri, Toni K.
    Albiges, Laurence
    Rini, Brian I.
    Atkins, Michael B.
    Schmidinger, Manuela
    Penkov, Konstantin
    Thomaidou, Despina
    Wang, Jing
    Mariani, Mariangela
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Exposure-response (E-R) analysis of efficacy for avelumab in combination with axitinib in patients with advanced renal cell carcinoma (aRCC) in JAVELIN Renal 101.
    Bello, Carlo
    Brar, Satjit
    Masters, Joanna C.
    Khandelwal, Akash
    Novakovic, Ana M.
    Ruiz-Garcia, Ana
    Hibma, Jennifer
    CANCER RESEARCH, 2021, 81 (13)
  • [25] Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.
    Froehner, Michael
    EUROPEAN UROLOGY, 2024, 86 (05)
  • [26] Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Motzer, Robert J.
    Penkov, Konstantin
    Haanen, John
    Rini, Brian
    Albiges, Laurence
    Campbell, Matthew T.
    Venugopal, Balaji
    Kollmannsberger, Christian
    Negrier, Sylvie
    Uemura, Motohide
    Lee, Jae L.
    Vasiliev, Aleksandr
    Miller, Wilson H., Jr.
    Gurney, Howard
    Schmidinger, Manuela
    Larkin, James
    Atkins, Michael B.
    Bedke, Jens
    Alekseev, Boris
    Wang, Jing
    Mariani, Mariangela
    Robbins, Paul B.
    Chudnovsky, Aleksander
    Fowst, Camilla
    Hariharan, Subramanian
    Huang, Bo
    di Pietro, Alessandra
    Choueiri, Toni K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1103 - 1115
  • [27] Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
    Haanen, J. B. A. G.
    Larkin, J.
    Choueiri, T. K.
    Albiges, L.
    Rini, B. I.
    Atkins, M. B.
    Schmidinger, M.
    Penkov, K.
    Michelon, E.
    Wang, J.
    Mariani, M.
    di Pietro, A.
    Motzer, R. J.
    ESMO OPEN, 2023, 8 (03)
  • [28] Final prespecified overall survival (OS) analysis of the phase 3 CLEAR trial: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients with advanced renal cell carcinoma (aRCC)
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jamie R.
    Goh, Jeffrey C.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Rodriguez-Lopez, Karla
    He, Cixin S.
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 72 - 73
  • [29] Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jaime R.
    Goh, Jeffrey C.
    Kapoor, Anil
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Rodriguez-Lopez, Karla
    He, Cixin S.
    Okpara, Chinyere
    McKenzie, Jodi
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
    Tomita, Y.
    Motzer, R. J.
    Choueiri, T. K.
    Rini, B., I
    Miyake, H.
    Uemura, H.
    Albiges, L.
    Fujii, Y.
    Umeyama, Y.
    Wang, J.
    Mariani, M.
    Schmidinger, M.
    ESMO OPEN, 2022, 7 (02)
12345